LARIMAR THERAPEUTICS INC (LRMR) Fundamental Analysis & Valuation

NASDAQ:LRMR • US5171251003

Current stock price

4.79 USD
+0.11 (+2.35%)
At close:
4.81 USD
+0.02 (+0.42%)
After Hours:

This LRMR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. LRMR Profitability Analysis

1.1 Basic Checks

  • LRMR had negative earnings in the past year.
  • In the past year LRMR has reported a negative cash flow from operations.
  • In the past 5 years LRMR always reported negative net income.
  • LRMR had a negative operating cash flow in each of the past 5 years.
LRMR Yearly Net Income VS EBIT VS OCF VS FCFLRMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • LRMR has a Return On Assets of -113.60%. This is in the lower half of the industry: LRMR underperforms 79.50% of its industry peers.
  • LRMR has a Return On Equity of -212.17%. This is in the lower half of the industry: LRMR underperforms 69.63% of its industry peers.
Industry RankSector Rank
ROA -113.6%
ROE -212.17%
ROIC N/A
ROA(3y)-64.12%
ROA(5y)-56.94%
ROE(3y)-101.43%
ROE(5y)-82.96%
ROIC(3y)N/A
ROIC(5y)N/A
LRMR Yearly ROA, ROE, ROICLRMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for LRMR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LRMR Yearly Profit, Operating, Gross MarginsLRMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. LRMR Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, LRMR has more shares outstanding
  • Compared to 5 years ago, LRMR has more shares outstanding
  • There is no outstanding debt for LRMR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LRMR Yearly Shares OutstandingLRMR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
LRMR Yearly Total Debt VS Total AssetsLRMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

  • LRMR has an Altman-Z score of -3.05. This is a bad value and indicates that LRMR is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of LRMR (-3.05) is comparable to the rest of the industry.
  • LRMR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.05
ROIC/WACCN/A
WACCN/A
LRMR Yearly LT Debt VS Equity VS FCFLRMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M 150M

2.3 Liquidity

  • A Current Ratio of 2.19 indicates that LRMR has no problem at all paying its short term obligations.
  • The Current ratio of LRMR (2.19) is worse than 74.27% of its industry peers.
  • LRMR has a Quick Ratio of 2.19. This indicates that LRMR is financially healthy and has no problem in meeting its short term obligations.
  • LRMR has a Quick ratio of 2.19. This is in the lower half of the industry: LRMR underperforms 72.34% of its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 2.19
LRMR Yearly Current Assets VS Current LiabilitesLRMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. LRMR Growth Analysis

3.1 Past

  • The earnings per share for LRMR have decreased strongly by -70.00% in the last year.
EPS 1Y (TTM)-70%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-62.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, LRMR will show a small growth in Earnings Per Share. The EPS will grow by 7.38% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y15.45%
EPS Next 2Y13.62%
EPS Next 3Y11.38%
EPS Next 5Y7.38%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LRMR Yearly Revenue VS EstimatesLRMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
LRMR Yearly EPS VS EstimatesLRMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

0

4. LRMR Valuation Analysis

4.1 Price/Earnings Ratio

  • LRMR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year LRMR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LRMR Price Earnings VS Forward Price EarningsLRMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LRMR Per share dataLRMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.62%
EPS Next 3Y11.38%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LRMR Dividend Analysis

5.1 Amount

  • LRMR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LRMR Fundamentals: All Metrics, Ratios and Statistics

LARIMAR THERAPEUTICS INC

NASDAQ:LRMR (4/2/2026, 8:00:01 PM)

After market: 4.81 +0.02 (+0.42%)

4.79

+0.11 (+2.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-19
Earnings (Next)04-28
Inst Owners86.04%
Inst Owner Change-11.09%
Ins Owners1.24%
Ins Owner Change7.14%
Market Cap496.20M
Revenue(TTM)N/A
Net Income(TTM)-165.67M
Analysts89.41
Price Target16.97 (254.28%)
Short Float %7.19%
Short Ratio1.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-44.6%
Min EPS beat(2)-48.03%
Max EPS beat(2)-41.16%
EPS beat(4)1
Avg EPS beat(4)-20.18%
Min EPS beat(4)-48.03%
Max EPS beat(4)16.29%
EPS beat(8)2
Avg EPS beat(8)-13.05%
EPS beat(12)5
Avg EPS beat(12)-5.9%
EPS beat(16)9
Avg EPS beat(16)-0.45%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.45%
PT rev (3m)0%
EPS NQ rev (1m)-7.77%
EPS NQ rev (3m)-4.07%
EPS NY rev (1m)-0.76%
EPS NY rev (3m)2.3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.35
P/tB 6.35
EV/EBITDA N/A
EPS(TTM)-2.21
EYN/A
EPS(NY)-1.87
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.09
OCFYN/A
SpS0
BVpS0.75
TBVpS0.75
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -113.6%
ROE -212.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.12%
ROA(5y)-56.94%
ROE(3y)-101.43%
ROE(5y)-82.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.19
Quick Ratio 2.19
Altman-Z -3.05
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)80.23%
Cap/Depr(5y)74.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-70%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-62.22%
EPS Next Y15.45%
EPS Next 2Y13.62%
EPS Next 3Y11.38%
EPS Next 5Y7.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-89.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.63%
EBIT Next 3Y17%
EBIT Next 5Y32.91%
FCF growth 1Y-58.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.98%
OCF growth 3YN/A
OCF growth 5YN/A

LARIMAR THERAPEUTICS INC / LRMR Fundamental Analysis FAQ

What is the fundamental rating for LRMR stock?

ChartMill assigns a fundamental rating of 2 / 10 to LRMR.


What is the valuation status for LRMR stock?

ChartMill assigns a valuation rating of 0 / 10 to LARIMAR THERAPEUTICS INC (LRMR). This can be considered as Overvalued.


How profitable is LARIMAR THERAPEUTICS INC (LRMR) stock?

LARIMAR THERAPEUTICS INC (LRMR) has a profitability rating of 0 / 10.


Can you provide the financial health for LRMR stock?

The financial health rating of LARIMAR THERAPEUTICS INC (LRMR) is 6 / 10.